John H. Ford

Deep value, special situations
John H. Ford
Deep value, special situations
Contributor since: 2011
Chanticleer: This $2 Stock Would Be Cheap At $6
Why Finjan Could Go From $6 To $15
Senesco: Near-Term Catalyst Could Double Shareprice
Opko's Billionaire CEO Invested In ChromaDex
22nd Century Is Worth Twice Today's Shareprice
Opko And Its Billionaire CEO Invested In Biozone
Why Marathon's Share Price Could Double This Year
MusclePharm Hits A Home Run
Will Apple Get Its Mojo Back?
Medbox Short Could Provide A 50% Return
Why MusclePharm Could Go From $4 To $20
Opko's 4KScore Could Generate Over $1.8 Billion Annually
Near-Term Catalyst Could Drive ChromaDex Shares Higher
Google Settlement Could Drive Vringo Shares Above $30
VirnetX Prevails Over Apple
Kodak's Sell-Off Is Overdone
Is The Kodak Name Worth $1 Billion?
VirnetX Owns The 4G Crown Jewels